ANI Pharmaceuticals ANIP Derivative assets
Derivative assets at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestRateDerivativeAssetsAtFairValue.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's derivative assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's derivative assets?
- ANI Pharmaceuticals (ANIP) reported derivative assets of $1.51M in Q1 2026.
- How has ANI Pharmaceuticals's derivative assets changed year-over-year?
- ANI Pharmaceuticals's derivative assets decreased by 58.1% year-over-year, from $3.61M to $1.51M.
- What is the long-term trend for ANI Pharmaceuticals's derivative assets?
- Over 3 years (2022 to 2025), ANI Pharmaceuticals's derivative assets has grown at a -42.7% compound annual growth rate (CAGR), from $8.76M to $1.65M.
- What does derivative assets mean?
- Fair value of derivative contracts (swaps, options, forwards, futures) in a net gain position — represents amounts owed to the firm by counterparties.